{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:52:05Z","timestamp":1794718325361,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13104-018-3599-8","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T10:18:05Z","timestamp":1532081885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Rethinking urinary antibiotic breakpoints: analysis of urinary antibiotic concentrations to treat multidrug resistant organisms"],"prefix":"10.1186","volume":"11","author":[{"given":"Daniel B.","family":"Chastain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Travis","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"issue":"1","key":"3599_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1\u201312.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3599_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajem.2016.10.034","volume":"35","author":"M Mazer-Amirshahi","year":"2017","unstructured":"Mazer-Amirshahi M, Pourmand A, May L. Newly approved antibiotics and antibiotics reserved for resistant infections: implications for emergency medicine. Am J Emerg Med. 2017;35(1):154\u20138.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"3599_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12941-017-0217-x","volume":"16","author":"DB Chastain","year":"2017","unstructured":"Chastain DB, Ngando IN, Bland CM, Franco-Paredes C, Hawkins WA. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital. Ann Clin Microbiol Antimicrob. 2017;16(1):43.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"7","key":"3599_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/cid\/cir031","volume":"52","author":"JD Turnidge","year":"2011","unstructured":"Turnidge JD. Subcommittee on antimicrobial susceptibility testing of the clinical and laboratory standards institute. Cefazolin and enterobacteriaceae: rational for revised susceptibility testing breakpoints. Clin Infect Dis. 2011;52(7):917\u201324.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3599_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics\u2013pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore. Clin Infect Dis. 2007;44(1):79\u201386.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3599_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1592\/phco.29.11.1326","volume":"29","author":"KM Kuper","year":"2009","unstructured":"Kuper KM, Boles DM, Mohr JF, Wanger A. Antimicrobial susceptibility testing: a primer for clinicians. Pharmacotherapy. 2009;29(11):1326\u201343.","journal-title":"Pharmacotherapy"},{"issue":"22","key":"3599_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM197411282912204","volume":"291","author":"TA Stamey","year":"1974","unstructured":"Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974;291(22):1159\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"3599_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","volume":"19","author":"N Frimodt-M\u00f8ller","year":"2002","unstructured":"Frimodt-M\u00f8ller N. Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002;19(6):546\u201353.","journal-title":"Int J Antimicrob Agents"},{"key":"3599_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-196501000-00001","volume":"44","author":"TA Stamey","year":"1965","unstructured":"Stamey TA, Govan DE, Palmer JM. The localization and treatment of urinary tract infections: the role of bactericidal urine levels as opposed to scrum levels. Medicine (Baltimore). 1965;44:1\u201336.","journal-title":"Medicine (Baltimore)"},{"issue":"272","key":"3599_CR10","first-page":"0137","volume":"20","author":"WR McCabe","year":"1965","unstructured":"McCabe WR, Jackson GG. Treatment of pyelonephritis: bacterial, drug and host factors in success or failure among 252 patients. N Engl J Med. 1965;20(272):0137\u201344.","journal-title":"N Engl J Med"},{"issue":"5","key":"3599_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/jac\/dkl368","volume":"58","author":"CAM McNulty","year":"2006","unstructured":"McNulty CAM, Richards J, Livermore DM, Little P, Charlett A, Freeman E, Harvey I, Thomas M. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother. 2006;58(5):1000\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3599_CR12","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O\u2019Grady NP, Bartlett JG, Carratal\u00e0 J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3599_CR13","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51\u201377.","journal-title":"Clin Infect Dis"},{"key":"3599_CR14","unstructured":"Rocephin (ceftriaxone) package insert. Lake Forest: Hospira Inc.; 2016."},{"issue":"3","key":"3599_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/AAC.36.3.552","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36(3):552\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3599_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/j.1552-4604.1985.tb02806.x","volume":"25","author":"DC Brittain","year":"1985","unstructured":"Brittain DC, Scully BE, McElrath MJ, Steinman R, Labthavikul P, Neu HC. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol. 1985;25(2):82\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3599_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clinthera.2009.01.013","volume":"31","author":"SJ Matthews","year":"2009","unstructured":"Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009;31(1):42\u201363.","journal-title":"Clin Ther"},{"issue":"2","key":"3599_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nprot.2007.521","volume":"3","author":"I Wiegand","year":"2008","unstructured":"Wiegand I, Hilpert K, Hancock RE. Agar and broth microdilution to determine the minimum inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163\u201375.","journal-title":"Nat Protoc"},{"key":"3599_CR19","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard. CLSI document M07\u2013A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard. CLSI document M07\u2013A10. 10th ed. Wayne: Clinical and Laboratory Standards Institute; 2015.","edition":"10"},{"issue":"1","key":"3599_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","volume":"27","author":"JD Turnidge","year":"1998","unstructured":"Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10\u201322.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3599_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bjid.2014.01.008","volume":"18","author":"FT Cuba","year":"2014","unstructured":"Cuba FT, Pignatari AC, Patekoski KS, Luchesi LJ, Kiffer CR. Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract. Braz J Infect Dis. 2014;18(5):512\u20137.","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"3599_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/antibiotics4040643","volume":"4","author":"SJ Tennant","year":"2015","unstructured":"Tennant SJ, Burgess DR, Rybak JM, Martin CA, Burgess DS. Utilizing Monte Carlo simulations to optimize institutional empiric antipseudomonal therapy. Antibiotics (Basel). 2015;4(4):643\u201352.","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"3599_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/600036","volume":"49","author":"DL Paterson","year":"2009","unstructured":"Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009;49(2):291\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3599_CR24","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1177\/106002809603001211","volume":"30","author":"MA Wynd","year":"1996","unstructured":"Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother. 1996;30(12):1414\u201324.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 2","key":"3599_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00003495-199958002-00006","volume":"58","author":"J Turnidge","year":"1999","unstructured":"Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(Suppl 2):29\u201336.","journal-title":"Drugs"},{"issue":"1","key":"3599_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jac\/35.1.129","volume":"35","author":"RG Masterson","year":"1995","unstructured":"Masterson RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7\u00a0days of co-trimazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother. 1995;35(1):129\u201337.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3599_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0002-9343(99)00026-1","volume":"106","author":"JM McCarty","year":"1999","unstructured":"McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M, Heyd A, Echols RM. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim\/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med. 1999;106(3):292\u20139.","journal-title":"Am J Med"},{"issue":"2","key":"3599_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jinf.2008.12.009","volume":"58","author":"ME Falagas","year":"2009","unstructured":"Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect. 2009;58(2):91\u2013102.","journal-title":"J Infect"},{"issue":"482","key":"3599_CR29","first-page":"729","volume":"52","author":"TC Christiaens","year":"2002","unstructured":"Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52(482):729\u201334.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"3599_CR30","doi-asserted-by":"publisher","first-page":"ofv159","DOI":"10.1093\/ofid\/ofv159","volume":"2","author":"L Grigoryan","year":"2015","unstructured":"Grigoryan L, Zoorob R, Wang H, Trautner BW. Low concordance with guidelines for treatment of acute cystitis in primary care. Open Forum Infect Dis. 2015;2(4):ofv159.","journal-title":"Open Forum Infect Dis."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-3599-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-018-3599-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-3599-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T23:09:52Z","timestamp":1563577792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-018-3599-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1186\/s13104-018-3599-8","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,20]]},"assertion":[{"value":"1 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"497"}}